Inotuzumab Ozogamicin as a Bridge to Stem Cell Transplantation in Relapsed Pediatric BCP‐ALL After Tisagenlecleucel: A Case Series
Open Access
- 14 March 2025
- journal article
- case report
- Published by Wiley in Cancer Reports
- Vol. 8 (3) , e70177
Abstract
Background: CD19‐directed chimeric antigen receptor T‐cell therapy tisagenlecleucel has shown promising results in the treatment of pediatric patients with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL). However, around 50% of patients relapse after tisagenlecleucel. Following multiple relapses, limited treatment options are left, and the prognosis is dismal. We report on four pediatric patients who relapsed after tisagenlecleucel and were treated with inotuzumab ozogamicin (InO).Case: Four patients with BCP‐ALL received tisagenlecleucel after second relapse (3/4) or refractory disease at first relapse (1/4). Three patients relapsed with CD19NEG/CD22POS BCP‐ALL, one with CD19POS/CD22POS BCP‐ALL. Following relapse, they received treatment with InO. After the first InO cycle, all achieved complete remission (CR), three without measurable residual disease. After two or three InO cycles, they underwent allogeneic hematopoietic stem cell transplantation (allo‐HSCT). One patient developed an isolated extramedullary relapse (IEM) in both anterior eye chambers six and nine months after allo‐HSCT and received palliative radiotherapy. This patient was in CR at the last follow‐up 25 months later. The other patients were also in CR at the last follow‐up (mean 31.3 months).Conclusion: InO can be used successfully and safely for the treatment of CD22POS BCP‐ALL relapse after tisagenlecleucel as a bridge to allo‐HSCT in heavily pretreated pediatric patients.Keywords
Funding Information
- KU Leuven (C14/18/104)
- Stichting Tegen Kanker
This publication has 19 references indexed in Scilit:
- A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)Blood, 2021
- Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphomaBlood Advances, 2020
- Childhood cancer mortality trends in Europe, 1990-2017, with focus on geographic differencesCancer Epidemiology, 2020
- Inotuzumab ozogamicin compassionate use for French paediatric patients with relapsed or refractory CD22‐positive B‐cell acute lymphoblastic leukaemiaBritish Journal of Haematology, 2020
- Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment StrategiesFrontiers in Immunology, 2019
- Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaLeukemia, 2018
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and TreatmentTransplantation and Cellular Therapy, 2016
- Trends in mortality from leukemia in Europe: An update to 2009 and a projection to 2012International Journal of Cancer, 2012
- Childhood Cancer Survival Trends in Europe: A EUROCARE Working Group StudyJournal of Clinical Oncology, 2005